Turkey: General Legal Framework Of Pharmaceutical Industry In Turkey

Introduction

Medicine has been defined by the World Health Organization as "products that are used to change or analyze physiological and pathological circumstances to the benefit of the user."1 Under Turkish law, medicine corresponds to "substance or a combination of substances of natural and/or synthetical origin applied to humans to cure a disease and/or prevent, to make a diagnosis or to restore, regulate or change a function."2

By nature, the pharmaceutical sector is a dynamic sector full of challenges and affected by scientific developments, research and development activities, and changing human needs. On the other hand, as the rewards increase along with the risks,3 the pharmaceutical sector is a profitable sector that adds value.

Global Pharmaceutical Sector

The global pharmaceutical sector has been experiencing rapid growth and development as a result of the acceleration of scientific developments and demographical changes. Average increase rates in annual health expenses between the years 2014-2018 has reached 2.4% in Western Europe, 4.9% in North America, 8.1% in Asia and Australia, and 8.7% in the Middle East and Africa4. This wind of change has triggered and will trigger other changes, both in an economic sense, as well as in terms of legal regulations in the pharmaceutical sector. Recent regulations are now based more on patient results and data-based information5. In the meanwhile, the share of generic drugs in the total drug expenses is expected to increase from 27% (corresponding to 261 billion dollars) as of 2012, to 36% (corresponding to 421 billion dollars) by 20176.

Pharmaceutical Sector in Turkey

The position of the pharmaceutical sector in our country has recently gained more significance, and has experienced a transformation, parallel to global changes7. There are 67 production facilities, approximately 300 corporations, 31 thousand employees, and more than 11 thousand products. Also, Turkish pharmaceutical products have been exported to more than 160 countries in the European Union, the Commonwealth of Independent States, North Africa and Middle Eastern countries8.

According to International Medical Statistics, Turkey has become the 17th worldwide with its pharmaceutical market of 7 billion dollars, in 20149. According to the same 2014 data, there are 332 firms active in the Turkish pharmaceutical sector, 56 of which are local firms, and 71 are also engaged in drug production10. The pharmaceutical sector is an intensively regulated sector, both globally and nationally. Licensing and repayment systems are examples of regulations to which this sector is subject11.

Licensing Process

The main duty of the regulatory bodies and authorities in the pharmaceutical sector (which is directly related to public health) is to analyze the reliability of the drugs, subject to approval in terms of their effectiveness and quality, and to ensure that they are accurately licensed. Following scientific research and development activities, before a newly developed drug is offered to the market, approval from all of the different authorized regulatory bodies in the pharmaceutical sector must be obtained.

In Turkey, the ministry authorized for the licensing of drugs is the Ministry of Health ("Ministry"). More specifically, the Turkish Drug and Medical Devices Administration is authorized for the determination and application of the rules and standards for licensing, storage, sales, import, export, market supply, distribution, putting into service, withdrawal and use of drugs12.

Licensing of drugs was initially regulated in Turkey by the Pharmaceuticals and Medical Preparations Law13 in 1928. Licensing of drugs are completed according to the Regulation Regarding the Licensing of Human Medicinal Products14 which entered into force 30 December 200515 ("Regulation"). According to the Regulation, a license is defined as "the document issued by the Ministry indicating that a product can be put into the market in accordance with the accepted product specifications stating its specific formula and pharmaceutical form and dose." On the other hand, licensing corresponds to the "analysis and approval process for a product to be placed into the market."16 The Regulation aims to "determine the practice with regard to the procedure and principles of the licensing process, and the practices for licensed human medicinal products, in order to provide that the human medicinal products have the required effectiveness, reliability and quality."

Evaluation of the License Application and Steps of Licensing

Before a drug attains its place in the market, it should be licensed upon the completion of all of the steps for licensing specified, below.

Preliminary Assessment: Following the receipt of an application filed by the Ministry, the applicant holder is notified of the required assessment within 30 days. If the application has been determined to have deficiencies, the application holder completes the application within 30 days. The second preliminary assessment following the elimination of the deficiencies before the Ministry is completed within 30 days17.

Licensing Period: The Ministry finalizes a full license application where the preliminary assessment has been completed, within 210 days following the acceptance of such application assessing whether the licensing conditions have been fulfilled18.

Licensing Criteria: Conditions to be taken into consideration regarding the products by the Ministry for the licensing of human medicinal products:

  • Proof of the effectiveness of the envisaged usage conditions,
  • Proof of reliability,
  • Suitable technical and pharmaceutical characteristics19.

Validity Period of the License: The license holder shall present all the information with regard to quality, reliability and effectiveness, including all the changes since the grant of the license along with the required pharmacovigilence data at least 3 months before the expiration of the first five years following the license date20. It is aimed that the extension of the validity period of the license is to be completed within 6 months at the latest21.

Liability of the License Holder: The license holder is liable to the Ministry with regard to the product subject to the license, in those matters such as the following:

  • Production of the product in accordance with the specifications stated under the annex of the application and accepted by the Ministry;
  • Update of the short product information and instructions for use in order to provide correct and secure usage; and
  • Providing availability of the product subject to the license22.

Also, the Ministry requires proof of bio-equivalence to grant license to generic drugs since 2000. As per those drugs produced before 2000 without bioequivalence certification, it has been requested that their bioequivalence is proven in a certain period of time23.

Repayment Systems

Types, amounts, expiration dates and procedures, and principles with regard to the repayment of the drugs refinanced by the Social Security Institution ("Institution") and those drugs, which have been requested to be refinances, are regulated under the Institution Repayment Regulation24.

The Social Security Institution General Health Insurance Alternative Repayment Regulation25 especially governs the alternative repayment models established to include those health related product and service groups financed/to be financed by the Institution in the repayment scheme and to subsidize the production of the market availability of the product groups, domestic production of exported products, and the provision of market availability as such.

With regard to the repayment scheme, drugs in each product group will receive repayment corresponding to a maximum of 10% more than the cheapest unit price. In addition, the base unit price will be applied to 15 equivalent groups26.

Conclusion and Future Projections

Health expenses per person between the years 2013-2017 will grow by 5.6% annual compound growth rate and Turkey will make a leap in the health sector with its rapid growth of the young population according to the future projections of the Economic Intelligence Unit27.

While the young population increases, the demographical structure of our country also changes, and the low level of drug consumption per person creates new opportunities for the pharmaceutical industry of Turkey in the future. In that sense, there is need for regulation in order to provide a reliable atmosphere for domestic and foreign investors and actors in the pharmaceutical sector, and to maintain and even increase the level of prosperity of the public28.

Footnotes

[1] İstanbul Eczacı Odası Gençlik Komisyonu http://www.istanbuleczaciodasi.org.tr/?cat=10&page=komisyon

[2] Madde 3(1)(g) - Sosyal Güvenlik Kurumu İlaç Geri Ödeme Yönetmeliği

[3] Risk/Reward Ratio Definition Investopedia, http://www.investopedia.com/terms/r/riskrewardratio.asp#ixzz4WlQulp00

[4] 2015 Global Yaşam Bilimleri Görünümü, Deloitte DTTL, 2014s https://www2.deloitte.com/content/dam/Deloitte/tr/Documents/life-sciences-health-care/sagl%C4%B1k-ve-ilac-sekt%C3%B6r%C3%BC-2020-ongoruleri.pdf ("Deloitte")

[5] Deloitte

[6] 2017'ye kadar Tıpta Genel Görünüm, IMS Sağlık Bilişim Kuruluşu

[7] Özellikle 2003 yılında uygulanmaya başlanan Sağlıkta Dönüşüm Programı'ndan sonra sağlık ve ilaç sektörlerindeki değişim hızlanmıştır. Bknz. Sağlıkta Dönüşüm Programı Ağustos 2008 İlerleme Raporu http://sbu.saglik.gov.tr/Ekutuphane/kitaplar/turkiyeSDP.pdf

[8] İlaç Endüstrisi İşverenler Sendikası, Türkiye İlaç Sektörü 2015, http://www.ieis.org.tr/ieis/assets/media/kls/TR_Ilac_sektoru_2015.pdf ("İlaç Endüstrisi İşverenler Sendikası")

[9] OECD Health Statistics 2016 Definitions, Sources and Methods

[10] İş Bankası İlaç Sektörü 2016/1 Raporu https://ekonomi.isbank.com.tr/UserFiles/pdf/sr201601_ilacsektoru.pdf ("İş Bankası")

[11] İş Bankası

[12] md. 27, Sağlık Bakanlığı Ve Bağlı Kuruluşlarının Teşkilat Ve Görevleri Hakkında Kanun Hükmünde Kararname, Karar Sayısı: KHK/663, Resmi Gazete ile Neşir ve İlânı: 2 Kasım 2011 - Sayı: 28103 (Mükerrer)

[13] KANUN NO: 1262 İSPENÇİYARİ VE TIBBİ MÜSTAHZARLAR KANUNU (*) Kabul Tarihi: 14 Mayıs 1928 Resmi Gazete ile Neşir ve İlânı: 26 Mayıs 1928 - Sayı: 898 3.t. Düstur, c.9 - s.544

[14] Sağlık Bakanlığından: BEŞERİ TIBBİ ÜRÜNLER RUHSATLANDIRMA YÖNETMELİĞİ
Dayandığı Kanun Numarası ve Tarihi: 1262 - 14.5.1928 / 3359 - 7.5.1987 / 5624 - 11.4.2007 / KKK/663 - 11.10.2011, sResmi Gazete ile Neşir ve İlânı: 19 Ocak 2005 - Sayı: 25705 ("Yönetmelik")

[15] İlaç Endüstrisi İşverenler Sendikası – Ruhsatlandırma http://www.ieis.org.tr/ieis/tr/issues/11/ruhsatlandirma

[16] Ruhsatlama Süreçlerinde Sağlık Bakanlığı Ve İlaç Sanayi İlişkileri, Yavuz UYAR İstanbul Üniversitesi Cerrahpaşa Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, İstanbul, 29.ANKEM Antibiyotik Ve Kemoterapi Kongresi, Bodrum, 28-31 Mayıs 2014 (http://www.ankemdernegi.org.tr/ANKEMJOURNALPDF/ANKEM_28_Ek2_2_6.pdf)

[17] Yönetmelik, md. 13.

[18] Yönetmelik, md. 15.

[19] Yönetmelik, md. 16.

[20] Yönetmelik, md. 21

[21] T.C. Sağlık Bakanlığı İlaç Ve Eczacılık Genel Müdürlüğü Kamu Hizmet Standartları Tablosu https://sgb.saglik.gov.tr/content/files/hizmetstandart/iegm_kamu_hizmet_standartlari.pdf

[22] Yönetmelik, md. 24

[23] Biyoeşdeğerlilik ve Jenerik İlaçlar Prof Dr. Öner Süzer, Cerrahpaşa Tıp Fakültesi, Farmakoloji ve Klinik Farmakoloji Anabilim Dalı http://www.onersuzer.net/eski/pdf/biyoesdegerlik_seminer.pdf

[24] Sosyal Güvenlik Kurumu İlaç Geri Ödeme Yönetmeliği
Dayandığı Kanun Numarası ve Tarihi: 5510 - 31.5.2006 / 5502 - 16.5.2006
Resmi Gazete ile Neşir ve İlânı: 10 Şubat 2016 - Sayı: 29620

[25] Sosyal Güvenlik Kurumundan: Sosyal Güvenlik Kurumu Genel Sağlık Sigortası Alternatif Geri Ödeme Yönetmeliği Dayandığı Kanun Numarası ve Tarihi: 5510 - 31.5.2006 / 5502 - 16.5.2006 Resmi Gazete ile Neşir ve İlânı: 10 Şubat 2016 - Sayı: 29620

[26] İlaç Endüstrisi İşverenler Sendikası, http://www.ieis.org.tr/ieis/tr/issues/10/geri-odeme

[27] Invest in Turkey – Yaşam Bilimleri T.C. Başbakanlık Türkiye Yatırım Destek ve Tanıtım Ajansı (TYDTA) http://www.invest.gov.tr/tr-tr/sectors/Pages/LifeSciencesAndHealthcare.aspx

[28] İş Bankası

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions